Why Intellia Therapeutics Shares Are Trading Higher Monday
Portfolio Pulse from Dylan Berman
Intellia Therapeutics (NASDAQ:NTLA) shares surged 11.2% after the company announced promising long-term data from its Phase 1 study of NTLA-2002, a CRISPR-based gene-editing therapy for hereditary angioedema (HAE). The single-dose treatment showed a 98% reduction in monthly HAE attacks and was well-tolerated with no severe side effects.
June 03, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics shares rose 11.2% following the release of positive long-term data from its Phase 1 study of NTLA-2002, a CRISPR-based therapy for hereditary angioedema. The treatment showed a 98% reduction in monthly HAE attacks and was well-tolerated.
The positive long-term data from the Phase 1 study of NTLA-2002 significantly boosts investor confidence in Intellia's CRISPR-based therapy, leading to a notable increase in the stock price. The 98% reduction in HAE attacks and the favorable safety profile are strong indicators of the treatment's potential success.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100